Hohneker John 4

What Happened
John Hohneker, a director of ArriVent BioPharma, was granted a derivative award representing 13,562 shares on 2026-06-18. The reported acquisition price is $0.00, so no cash was paid. This filing shows an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; reported on Form 4 filed 2026-06-22 (timely).
• Price: $0.00 per share; total cash paid = $0.00.
• Shares involved: 13,562 (derivative award).
• Shares owned following the transaction: Not specified in the provided summary.
• Footnote: F1 — the shares underlying this award vest on the first anniversary of the grant date, subject to Hohneker’s continued service through the vesting date.
• Transaction code meaning: A = Award/Grant (derivative interest).

Context
This was a compensation-related grant to a company director; such awards are common for director compensation and do not by themselves indicate a buy or sell decision in the market. Because the award vests over time, the economic benefit depends on continued service and future vesting. The filing appears timely under Form 4 rules.